Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Investment Perspective

Scancell is an oncology-focussed clinical stage immunology specialist. It has two promising vaccine platforms, ImmunoBody and Moditope, and two antibody technologies, GlyMab (anti-glycans) and AvidiMab, with the potential to treat many solid cancers, either as monotherapy or in combination. Modi-1, the first Moditope programme, is expected to start Phase I/II trials targeting hard-to-treat tumours during H122. The lead ImmunoBody programme, SCIB1, is in a Phase II combination study in metastatic melanoma. The broad acting glycan antibodies are at earlier stages of development and will likely be partnered for clinical studies. AvidiMab technology will be increasingly employed to enhance avidity and potency, with the Phase I COVIDITY COVID-19 vaccine programme the most high-profile beneficiary. Our Scancell valuation, using a risk adjusted DCF model, is £237.4m, or 29.1p per share.

Market information

SymbolPrimary exchanges


A fresh impetus in delivering immune-oncology vaccines
Outlook | 12 Apr 2022
CTA approval confirms H221 COVIDITY Phase I start
Lighthouse | 30 Jul 2021
COVIDITY programme to start Phase I in H221
Lighthouse | 22 Jun 2021

Recent News

Modi-1 Phase 1/2 trial open for recruitment
11 Apr 2022
Update on COVIDITY trial
29 Mar 2022
Scancell progresses its new anti-glycan mAb
17 Mar 2022
Update on COVIDITY Phase I trial
31 Jan 2022